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Elucidation of molecular mechanisms underlying the aberrant phosphatidylcholine 
cycle in cancer cells plays in favor of the use of metabolic imaging in oncology and 
opens the way for designing new targeted therapies. The anomalous choline metabolic 
profile detected in cancer by magnetic resonance spectroscopy and spectroscopic 
imaging provides molecular signatures of tumor progression and response to therapy. 
The increased level of intracellular phosphocholine (PCho) typically detected in cancer 
cells is mainly attributed to upregulation of choline kinase, responsible for choline phos-
phorylation in the biosynthetic Kennedy pathway, but can also be partly produced by 
activation of phosphatidylcholine-specific phospholipase C (PC-PLC). This hydrolytic 
enzyme, known for implications in bacterial infection and in plant survival to hostile envi-
ronmental conditions, is reported to be activated in mitogen- and oncogene-induced 
phosphatidylcholine cycles in mammalian cells, with effects on cell signaling, cell cycle 
regulation, and cell proliferation. Recent investigations showed that PC-PLC activation 
could account for 20–50% of the intracellular PCho production in ovarian and breast 
cancer cells of different subtypes. Enzyme activation was associated with PC-PLC 
protein overexpression and subcellular redistribution in these cancer cells compared 
with non-tumoral counterparts. Moreover, PC-PLC coimmunoprecipitated with the 
human epidermal growth factor receptor-2 (HER2) and EGFR in HER2-overexpressing 
breast and ovarian cancer cells, while pharmacological PC-PLC inhibition resulted into 
long-lasting HER2 downregulation, retarded receptor re-expression on plasma mem-
brane and antiproliferative effects. This body of evidence points to PC-PLC as a potential 
target for newly designed therapies, whose effects can be preclinically and clinically 
monitored by metabolic imaging methods.
Keywords: choline metabolism, phosphatidylcholine phospholipase c, choline kinase, breast cancer, ovarian 
cancer, magnetic resonance spectroscopy, targeted therapy
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PHOsPHAtiDYLcHOLiNe-sPeciFic 
PHOsPHOLiPAse c iN LiviNG sYsteMs
Phosphatidylcholine-specific phospholipase C (EC 3.1.4.3, here 
abbreviated as PC-PLC) is responsible for hydrolysis of this 
glycerophospholipid into phosphocholine (PCho) and 1,2-dia-
cylglycerols (DAG).
Phospholipases of this class are known to be important secreted 
pathogenicity factors in some bacteria, parasites, and fungi (1, 2) in 
which they act as lytic agents against eukaryotic cells and interfere 
with the host immune defense. Some bacterial PC-PLCs are also 
involved in lipid remodeling in response to phosphate-limiting 
conditions. Amino acid sequences and encoding genes have been 
identified for various toxic and non-toxic PC-PLCs produced by 
Gram-positive and Gram-negative bacteria. Since some PC-PLCs 
play important roles in the pathogenesis of diseases, they could 
also form components of vaccines.
Phospholipases C endowed with a broader substrate specificity 
(collectively called NPC, as an acronym for “non-specific phos-
pholipases C”) were discovered, sequenced, and cloned in plants 
as a novel family of phospholipid-cleaving enzymes homologous 
to bacterial PC-PLCs and responsible for lipid conversion under 
phosphate-limiting conditions (3). Notably, phosphatidylcholine-
hydrolyzing members of the NPC family in Arabidopsis were 
implicated in stress response to phytohormones, root develop-
ment, and tolerance to adverse environmental conditions (3).
Phosphatidylcholine-specific phospholipase C activity is 
reported to be an essential source of phospholipid-derived 
signaling in animal cells (4, 5) in which this phospholipase can 
be implicated in various intracellular regulatory mechanisms, 
including long-term cell response to mitogens (6–9); cell cycle 
regulation and cell proliferation (8, 10, 11); programmed cell 
death (12, 13); activation of cells of the immune system (14–22); 
cell transformation (23, 24); oncogene-driven cell signaling and 
tumor progression (25–28); and cell differentiation of tumoral 
and non-tumoral cells (29–34).
Phosphatidylcholine-specific phospholipase C isoforms of 
varying molecular weights have been isolated from mammalian 
sources (35–37). However, differently from phosphatidylinositol-
bis-phosphate specific PLCs (PIP2-PLCs), well-recognized key 
regulatory enzymes of cell growth, development, and stress 
responses in living organisms, a slower progress has been so far 
achieved in the molecular characterization of PC-PLCs in animal 
cells, in which these phospholipases have not yet been sequenced 
and cloned. For these reasons, the role of PC-PLCs in mammalian 
cells has remained elusive until recently. Despite these limitations, 
the PC-PLC protein expression could be effectively investigated 
in mammalian cells using cross-reacting polyclonal antibodies 
raised in rabbits against bacterial PC-PLCs, as first described 
by Clark et  al. (37). Using these antibodies, a 66-kDa PC-PLC 
isoform has been detected in various mammalian cell systems, 
such as mouse NIH-3T3 fibroblasts (8, 38), synaptic endings (39, 
40), epithelial ovarian cancer (EOC) cells and surgical specimens 
(26, 27), breast cancer (BC) (28) and hepatoma cells (11, 30, 
41). Furthermore, near-infrared probes capable to non-invasively 
detect PC-PLC in experimental animals have been developed and 
their utility tested for in vivo cancer imaging (42).
An increasing interest in filling the existing gaps in the molecu-
lar and genomic characterization of mammalian PC-PLCs arises 
from accruing evidence that protein overexpression, subcel-
lular redistribution, and activation of this enzyme in tumor cells 
represent relevant features of the aberrant choline phospholipid 
metabolism in cancer (43). In addition, evidence for a physical 
interaction of PC-PLC with the human epidermal growth factor 
receptor-2 (HER2) and EGFR is provided by coimmunopre-
cipitation tests on HER2-overexpressing BC (28) and EOC cells.1 
Pharmacological PC-PLC inhibition is associated in these cells 
with long-lasting HER2 downmodulation and induction of 
antiproliferative effects, suggesting a role for PC-PLC activity in 
controlling HER2-driven tumorigenicity. Furthermore, inhibi-
tion of PC-PLC is associated with loss of mesenchymal traits in 
the highly metastatic triple-negative MDA-MB-231 cells and with 
decreased in vitro cell migration and invasion capabilities, sug-
gesting a pivotal role for PC-PLC in BC cell differentiation (34).
This article provides a brief overview on metabolic and func-
tional features of PC-PLC in BC and EOC cells and outlines some 
perspectives offered by further elucidation of the impact of this 
phospholipase on cancer cell biology and therapy targeting.
Pc-PLc iN BreAst AND OvAriAN 
cANcer ceLLs
Pc-PLc Activation and contribution to 
elevated Phosphocholine Production
Phosphatidylcholine, the most abundant phospholipid of eukary-
otic cells, plays the double role of basic structural component 
of cell membranes and precursor of agonist-induced signaling 
lipids (44) through a network of enzymatic reactions known as 
the phosphatidylcholine cycle (45) (scheme in Figure  1). The 
agonist-induced production and utilization within this cycle of 
signaling lipids, such as DAG, phosphatidate, lysophosphatidyl-
choline, and arachidonic acid, are associated with changes in the 
fluxes and steady-state levels of water-soluble phosphatidylcho-
line metabolites, such as PCho, glycerophosphocholine (GPCho), 
and free choline (Cho), main components of the so-called total 
choline (tCho) metabolic profile.
Magnetic resonance spectroscopy (MRS) and spectroscopic 
imaging (MRSI) represent powerful means to detect changes 
induced in the tCho pool by oncogene-driven activation of 
phosphatidylcholine cycle enzymes in cancer and to evaluate 
the response of the tCho profile to agents targeted against 
selected enzymes (43, 46–48). Figure  1 shows examples of 
(i)  the 1H-MRS tCho profile in aqueous extracts of normal 
ovarian surface epithelial cells (OSE, Figure  1A) compared 
with the EOC cell line SKOV3 and its in vivo-passaged cell vari-
ant SKOV3.ip, characterized by higher HER2 overexpression 
(Figure 1B) and enhanced in vivo tumorigenicity (25, 27, 49, 
50); (ii) the effects induced on the SKOV3.ip tCho profile by cell 
exposure to D609, a competitive PC-PLC inhibitor (Figure 1C); 
1 Paris L, Podo F, Spadaro F, Abalsamo L, Pisanu ME, Ricci A, et  al. 
Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-
overexpression and tumor growth in a highly tumorigenic ovarian cancer model. 
Manuscript in preparation (2016).
FiGUre 1 | Detection of the 1H-Mrs total choline (tcho) metabolic profile in epithelial ovarian cancer (eOc) cells and in Mrs/Mrsi clinical 
examinations. The phosphatidylcholine cycle and its links with tyrosine kinase receptors’ stimulation, post-receptor signaling pathways, and cancer cell biological 
features are sketched in the central scheme. (A–c) High resolution 9.4-T 1H-MRS tCho profile of aqueous extracts of (A) ovarian surface epithelial cells (OSE); 
(B) SKOV3 cell line and its in vivo-passaged cell variant SKOV3.ip, characterized by higher in vivo tumorigenicity and twofold higher HER2 protein expression level 
(in the insert, Western blot analysis of HER2, 185 kDa); (c) SKOV3.ip cells exposed for 24 h to the competitive PC-PLC inhibitor D609, compared with control 
untreated cells. (D) Absolute activity rates (nmol/106 cells × h, mean ± SD) of ChoK and PC-PLC measured in aqueous extracts of different EOC cell lines, 
compared with those of non-tumoral immortalized hTERT cells (number of independent experiments, n ≥ 3 for all cell lines). (e,F) Examples of in vivo detection of 
(e) 1H-MRS tCho peak (3.2 ppm) in a single voxel and (F) tCho map obtained by MRSI in EOC patient examined at 1.5 T. For further details, see Ref. (25, 27, 
49–51). The central scheme was adapted from Figure 1 of Ref. (43). Abbreviations: Enzymes: ChoK, choline kinase (EC 2.7.1.32); CT, cytidylyltransferase 
(EC 2.7.7.15); LPL, lysophospholipase (EC 3.1.1.5); PCT, phosphocholine transferase (EC 2.7.8.2); PD, glycerophosphocholine phosphodiesterase (EC 3.1.4.2); 
PLA1, phospholipase A1 (EC 3.1.1.32); PLA2, phospholipase A2 (EC 3.1.1.4); PLC, phosphatidylcholine-specific phospholipase C (EC 3.1.4.3); PLD, phospholipase 
D (EC 3.1.4.4). Metabolites: AA, arachidonic acid; CDP-Cho, cytidine diphosphate-choline; Cho, free choline; DAG, diacylglycerol; GroP, sn-glycerol-3-phosphate; 
GPCho, glycerophosphocholine; Ino, myo-inositol; LPA, lysophosphatidate; LPtdCho, lysophosphatidylcholine; PA, phosphatidate; PCho, phosphocholine; PtdCho, 
phosphatidylcholine; tCho, total choline-containing metabolites (GPCho + PCho + Cho). Transporters: CHT, choline high-affinity transporters; CTL, choline 
transporter-like proteins; OCT, organic cation transporters.
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(iii) the simultaneous activation of ChoK and PC-PLC in differ-
ent EOC cell lines versus hTERT, a non-tumoral immortalized 
ovarian cell line (Figure 1D); and (iv) examples of in vivo detec-
tion of the 1H-MRS tCho peak (3.2  ppm) in a selected voxel 
(Figure 1E) and a tCho map obtained by 3D-MRSI in a EOC 
patient (Figure 1F) (51).
The 1H-MRS PCho signal increased 3.6- to 6.5-fold in the 
investigated EOC cell lines compared with non-tumoral coun-
terparts (25, 27, 50). Notably, the 2-fold higher HER2 expression 
of SKOV3.ip versus SKOV3 cells was associated with a 1.7-fold 
higher PCho content (50). An elevated PCho level was the princi-
pal cause of the higher tCho pool detected in these cancer cells, in 
agreement with the general view that an increased tCho represents 
a metabolic signature of malignancy (43, 46–48, 52,  53). The 
enhanced PCho production in cancer cells is currently attributed 
to the upregulation of choline kinase (43, 46), the enzyme com-
mitted to choline phosphorylation in the biosynthetic Kennedy 
pathway. This enzyme (notably the ChoK-alpha isoform) has been 
proposed as a new target for cancer therapy (54, 55). A substantial 
contribution to the production of the intracellular PCho pool 
in cancer cells may, however, also derive from PC-PLC activa-
tion (see scheme in Figure 1). The question therefore arises on 
the relative contributions possibly given by PC-PLC activation 
to PCho production in different EOC cells. Measurements in 
FiGUre 2 | subcellular localization of Pc-PLc in human Bc cell lines. 
(A) PC-PLC activity rates (nmol/mg protein × h, mean ± SD, n ≥ 3) 
measured in MCF-7, SKBr3, and MDA-MB-231 BC cell lines, possessing 
different levels of HER2 and EGFR expression, compared with that of the 
human mammary epithelial cell line of fibrocystic origin MCF-10. (B) Confocal 
laser scanning microscopy (CLSM) examinations (3D reconstruction images) 
of the same cell lines as in (A). Cells were either fixed and permeabilized 
(upper panels, scale bars 20 μm) or maintained unfixed (bottom panels, scale 
bars 5 μm) and stained for PC-PLC detection with rabbit anti-PC-PLC 
antibodies (pseudo-color gray); nuclei were stained with DAPI (blue). (c) 
Colocalization of PC-PLC and HER2 on plasma membrane of SKBr3 cells. 
CLSM detection of PC-PLC and HER2 was performed on fixed and 
permeabilized (upper panels) or unfixed cells (bottom panels, 3D 
reconstruction images) using rabbit polyclonal anti-PC-PLC antibodies 
(green) and anti-HER2 W6/100 monoclonal antibody (red). Colocalization 
areas are represented in yellow. Scale bars, 8 μm. (D) HER2 downmodulation 
in SKBr3 cells exposed for different time intervals to the competitive PC-PLC 
inhibitor D609. CLSM analyses of unfixed SKBr3 cells cultured in complete 
medium in absence (t = 0) or presence of D609 (6 and 24 h). After washing, 
cells were stained with anti-PC-PLC (green) and anti-HER2 antibodies (red). 
For further details, see Ref. (28, 34).
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our laboratory (Figure  1D) showed that a mean 12- to 24-fold 
activation of ChoK was paralleled by a 10- to 30-fold activation 
of PC-PLC in four EOC cell lines (IGROV1, OVCAR3, SKOV3, 
and SKOV3.ip) versus the non-tumoral hTERT cell line (in which 
both enzymes had a basal activity of about 0.5 nmol/106 cells × h). 
In some EOC cell lines (IGROV1, SKOV3.ip), ChoK and PC-PLC 
showed very similar activity rates, suggesting about equal contri-
butions of the two enzymes to the PCho production. Accordingly, 
there was a 40–50% decrease of the PCho signal in SKOV3.ip cells 
following 24-h exposure to the competitive PC-PLC inhibitor 
D609 (example in Figure  1C). In another cell line (OVCAR3), 
the mean activity rate of ChoK was instead fourfold higher than 
that of PC-PLC. Overall, these data showed that the contribution 
of PC-PLC to the PCho production could vary, according to the 
cell line, between 20% and 50%, in substantial agreement with 
the effects of D609 or si-RNA ChoK silencing on the PCho levels 
measured in different EOC cells [Figure 1C; (27, 56)].
This body of evidence supports the conclusion that PC-PLC 
can contribute to a substantial extent to the accumulation of PCho 
in EOC cells. This evidence may allow a better interpretation of 
changes occurring in the in vivo MRS- and MRSI-detected tCho 
peak in preclinical EOC models (57) and in EOC clinical lesions 
(examples in Figures 1E,F) during tumor progression, response 
to treatment, or relapse.
Regarding human BC cells, a significant 2- to 5.5-fold ChoK 
activation was detected by Eliyahu and colleagues in cell lines of 
different subtypes (58), such as luminal-A MCF-7, HER2-positive 
SKBr3, and basal-like EGFR-positive MDA-MB-231 (respective 
activity rates 21 ± 3, 43 ± 6, and 17 ± 2 nmol/mg protein × h), 
versus mammary epithelial cells (8.0 ± 2.0 nmol/mg protein × h). 
Enzymatic assays in our laboratory (34) showed threefold to 
sixfold higher PC-PLC activity rates (ranging between 12 ±  2 
and 22 ± 4 nmol/mg protein × h) in these BC cells versus the 
fibrocystic MCF-10 cell line (Figure 2A). Overall, these data sug-
gest that the contribution of PC-PLC to the intracellular PCho 
production also varied in these BC cells between 20% and 50%, 
as reported above for EOC cell lines.
Pc-PLc Overexpression and subcellular 
redistribution
Western blot analyses showed that the reported threefold to six-
fold activation of PC-PLC in BC cell lines was associated with a 
threefold to sixfold elevated PC-PLC protein expression (34), the 
highest value being detected in the triple-negative MDA-MB-231 
cells. Confocal laser scanning microscopy (CLSM) of fixed and 
permeabilized cancer cells (Figure 2B, top panels) showed that the 
enzyme was localized both in nuclear and cytoplasmic compart-
ments. Only a few PC-PLC-positive granules, mainly localized in 
perinuclear areas and absent in the nuclear matrix, were instead 
detected in the non-tumoral MCF-10A cells. CLSM of unfixed cells 
showed that PC-PLC massively accumulated on plasma membrane 
of the HER2-positive SKBr3 cells, but not on that of cells with basal 
HER2 expression (Figure 2B, bottom panels). PC-PLC extensively 
colocalized with HER2 in raft domains of plasma membrane of 
SKBr3 cells [Figure  2C; (28)], in which coimmunoprecipitation 
tests showed a physical association of PC-PLC with HER2 and with 
other members of the ErbB family, such as EGFR and HER3.
Regarding PC-PLC distribution in EOC cells, a massive accu-
mulation of this phospholipase was detected by CLSM on plasma 
membrane of all investigated cell lines and on that of cancer cells 
isolated from patient peritoneal exudate, but not on OSE cells (26). 
5Podo et al. PC-PLC Activation in Cancer Cells
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The enzyme extensively colocalized with β1-integrin in non-raft 
domains of EOC cells (26). The extent of colocalization of the two 
proteins substantially decreased on membrane of serum-deprived 
cancer cells, but returned to the original level upon cell restimula-
tion by platelet-derived growth factor. These data warrant further 
investigations on the functional role of the interaction between 
PC-PLC and β1-integrin, an adhesion protein well-known for 
its involvement in metastatic spread (59). Furthermore, CLSM 
and coimmunoprecipitation experiments showed an extensive 
colocalization and physical association of PC-PLC with HER2 
on plasma membrane of SKOV3 and SKOV3.ip cells, confirming 
the interest of further investigating the role of this phospholipase 
in regulating HER2 overexpression in ovarian cancer.
effects of Pc-PLc inhibition
Exposure of BC cell lines to D609 led to cell proliferation arrest, 
changes in cell morphology, and formation of lipid bodies typical 
of BC cell differentiation (34). Moreover, in the poorly differenti-
ated MDA-MB-231 cells, PC-PLC inhibition was associated with 
progressive decreases of mesenchymal traits, such as vimentin 
and N-cadherin expression, reduced galectin-3 and milk fat 
globule EGF-factor 8 levels, β-casein formation, and decrease of 
in vitro cell migration and invasion (34). We therefore proposed 
that the inhibition of this phospholipase can be envisaged as a 
means to promote differentiation of metastatic BC cells, with 
potential therapeutic effects.
Besides inducing cell differentiation, exposure of SKBr3 
cells to D609 resulted in a progressive downmodulation of both 
HER2 and PC-PLC on plasma membrane, an effect already 
evident at 6  h and almost complete at 24  h (Figure  2D). This 
effect was associated with HER2 internalization and lysosomal 
degradation, long-lasting retardation of re-expression of this 
receptor on membrane, and an about 50% decrease in the overall 
protein expression (28). Notably, no substantial influence on 
HER2 externalization is known to be exerted in these cells using 
Trastuzumab (60), the anti-HER2 humanized monoclonal anti-
body mostly used at the clinical level, whose in vivo therapeutic 
efficacy is mainly attributed to antibody-mediated cytotoxicity. 
This body of evidence suggests that PC-PLC inhibition may be 
envisaged as a potential alternative approach to counteract the 
tumorigenic effects of HER2, especially in cases of resistance (or 
contraindication) to current anti-HER2 treatment.
Long-standing decreases of HER2 and phospho-HER2 
contents, reduced HER2 mRNA expression, and cell cycle arrest 
were also detected in the highly tumorigenic SKOV3.ip EOC cells 
exposed to a non-apoptotic dose of D6091. Furthermore, reduced 
tumor growth and decrease in HER2 and Ki67 immunostaining 
were detected in SKOV3.ip xenografts upon in  vivo treatment 
with D609, pointing to the interest of further evaluating the 
potential role of PC-PLC as a therapy target in preclinical HER2-
overexpressing EOC models.
FUtUre reseArcH DirectiONs
In summary, PC-PLC is overexpressed and activated in BC and 
EOC cells, and pharmacological PC-PLC inhibition can lead 
to downregulation of HER2 and induction of antiproliferative 
effects. Furthermore, cell differentiation and decreases in cell 
migration and invasion were induced in the highly metastatic 
MDA-MB-231 BC cell line exposed to the PC-PLC inhibitor. 
These findings point to PC-PLC as a potential target (or cotarget) 
for anticancer therapy, especially in cases of resistance or con-
traindications to currently adopted treatments. In this context, 
the following issues appear worth of further elucidation:
Molecular Mechanisms responsible for 
Oncogene-Driven Pc-PLc Activation and 
impact on Molecular imaging
The 1.7-fold increase in PC-PLC activity in a SKOV3 cell variant 
(SKOV3.ip) endowed with a 2-fold higher HER2 overexpres-
sion (50) and the over 3-fold increase in PC-PLC activity in 
the HER2-positive SKBr3 cells (34) warrant further investiga-
tions on the molecular mechanisms linking PC-PLC activation 
with HER2 overexpression and oncogenic effects of HER2 and 
HER2–EGFR heterodimers. Interestingly, the PC-PLC inhibitor 
D609, but not Trastuzumab, induced decreases of HER2 expres-
sion and cell proliferation in the Trastuzumab-resistant SKBr3 
cell line. Conversely D609, either alone or in combination with 
Trastuzumab, induced in the Trastuzumab-sensitive BT-474 cells 
a decrease in cell proliferation comparable to that induced using 
Trastuzumab alone (28).
The sixfold activation of PC-PLC in MDA-MB-231 BC cells 
and its strong nuclear localization (Figures  2A,B) warrant 
investigations on the relationships between PC-PLC and EGFR 
overexpression in triple-negative BC cells and their metastatic 
derivatives.
Overexpression of EGFR and c-Src in BC cells has been 
reported to synergistically increase ChoK-alpha protein expres-
sion and activity levels (61). Further elucidation of EGFR-driven 
mechanisms responsible for the activation of both ChoK-alpha or 
PC-PLC in BC cells may lead to novel multi-targeted anticancer 
therapies, whose effects could be preclinically and clinically moni-
tored by MRS-based and optical metabolic imaging methods.
Integration of MRS with 11C or 18F choline-based positron 
emission tomography (PET) may allow discrimination of the 
contributions to PCho production, provided by the biosynthetic 
and catabolic pathways, respectively. In fact, while both ChoK 
and PC-PLC can contribute to the MRS-detected PCho signal, 
the choline-PET standardized uptake value (SUV) mainly reflects 
choline transport and phosphorylation in the Kennedy pathway, 
with negligible contributions from products of radiolabeled 
phosphatidylcholine catabolism in a time window of about 1 h 
(the duration of a typical choline-PET examination) (43).
Molecular and Functional characterization 
of the interaction between Pc-PLc and 
receptors of the erbB Family
The interaction of an activated PC-PLC isoform with HER2, 
detected by coimmunoprecipitation tests, appears essential to the 
functional localization of this receptor in BC cells, since PC-PLC 
inhibition induces a long-lasting HER2 downmodulation (28). 
The association of these effects with reduced cell proliferation, 
induction of cell differentiation, and decrease in cell migration 
6Podo et al. PC-PLC Activation in Cancer Cells
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and invasion suggests that an activated PC-PLC may act as a 
sort of chaperone for HER2. A local overproduction of DAG 
by enhanced PC-PLC-mediated phosphatidylcholine hydrolysis 
could mediate this action. A local accumulation of DAG can, in 
fact, perturb the phospholipid bilayer, alter protein-lipid interac-
tions, and influence the formation of microdomains, thus modi-
fying the exposure of surface membrane receptors and affecting 
their recycling between membrane and inner cell compartments 
(62, 63). Interestingly, ChoK-alpha has also been proposed to 
act as a chaperone for the androgen receptor, a ligand-inducible 
transcription factor of the nuclear hormone receptor superfamily, 
critically involved in prostate cancer progression (64). The newly 
suggested role of ChoK and PC-PLC as regulators of expression 
for oncogenes and growth factor receptors may lead to new 
targeted or multi-targeted anticancer therapies.
structural and Genomic characterization 
of Pc-PLc isoforms Active in cancer cells
This body of evidence points to the need for overcoming the 
current limitations deriving from (a) the scarce attention so 
far devoted to the genomic and structural characterization of 
mammalian PC-PLC isoforms and (b) the availability until 
now of only one PC-PLC inhibitor, D609, a synthetic tricyclic 
compound having a xanthate group, possessing antiviral, 
anti-tumor, anti-inflammatory, and anti-apoptosis properties 
and used as a lipid-related enzyme inhibitor for the past three 
decades (65).
Steps forward in translational oncology may be expected from:
(a) investigating the role of PC-PLC expression and the effects 
of PC-PLC inhibition in BC and EOC stem cells, to identify 
potential ways to reinforce therapeutic strategies aimed to 
eradicate malignancies (66, 67);
(b) exploring in preclinical models the correlation between 
PC-PLC activity and disease progression or response to 
therapy, as a ground for evaluating the impact of PC-PLC 
activation on clinical outcome.
cONcLUsiON
Recent evidence shows protein overexpression and enzymatic 
activation of PC-PLC in BC and EOC cells compared with non-
tumoral counterparts.
The activation of PC-PLC can contribute to 20–50% of the 
production of intracellular PCho in BC and EOC cells.
Phosphatidylcholine-specific phospholipase C activation is 
associated in these cancer cells with its protein overexpression 
and subcellular redistribution, the underlying molecular mecha-
nisms deserving further elucidation.
Phosphatidylcholine-specific phospholipase C interacts with 
HER2 and EGFR in HER2-overexpressing BC and EOC cells, 
while its pharmacologic inhibition may play a pivotal role in 
HER2 downmodulation, reduction of cell proliferation, and 
cancer cell differentiation.
Overall, this body of evidence supports the interest of evaluat-
ing the possible role of this phospholipase as a key metabolic 
target for anticancer therapy.
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